AP Pharma Reports FDA Acceptance Of APF530
FDA has accepted to review AP Pharma’s New Drug Application (NDA) for APF530, for the potential treatment of chemotherapy-induced nausea and vomiting (CINV). APF530 is a long-acting formulation
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
CareFusion has expanded its Pyxis Perioperative offerings that integrate with operating room information systems (ORIS), incorporate radio-frequency identification (RFID) technology, and include new services. Rusty Frantz, general manager